首页工具

登录

4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc)

产品编号 TMPY-05376

别名: 4-1BB, tumor necrosis factor receptor superfamily, member 9, CDw137, CD137, ILA

4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44 kDa and the accession number is Q07011.

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

TargetMol

4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc)

规格	价格/CNY		货期	数量
100 μg	￥ 2,560		现货
200 μg	￥ 4,540		5日内发货
500 μg	￥ 9,610		5日内发货

大包装超大折扣，点击咨询

选择批次

COA DATASHEET SDS

更多批次查询请联系客服

生物活性

技术参数

产品性质

参考文献

生物活性	Measured by its binding ability in a functional ELISA. Immobilized TNFRSF9-Fc at 10 μg/ml(100 μl/well) can bind TNFSF9/Biotin , The EC50 of TNFSF9/Biotin is 20-60 ng/mL.
产品描述	4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 44 kDa and the accession number is Q07011.

种属	Human
表达系统	HEK293 Cells
标签	C-hFc
蛋白编号	Q07011
别名	4-1BB, tumor necrosis factor receptor superfamily, member 9, CDw137, CD137, ILA
蛋白构建	The Human TNFRSF9 (NP_001552.2) (Met1-Gln186) was expressed with the Fc region of Human IgG1 at the C-terminus.
蛋白纯度	≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.
分子量	44 kDa (predicted)

内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.
复溶方法	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted protein solutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice.
研究背景	CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+and CD8+T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy

参考文献

1. Sica G,et al.(1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9. 2. Nam KO,et al.(2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63. 3. Wang Q,et al.(2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200. 4. Melero I,et al.(2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90. 5. Thum E,et al.(2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.

计算器

复溶计算器

重组蛋白稀释计算器

比活力计算器

Volume (to add to vial)

=

Mass (in vial)

÷

Desired Reconstitution Concentration

bottom

技术支持

您可能有的问题的答案可以在重组蛋白操作手册中找到

Keywords

4-1BB/CD137/TNFRSF9 Protein, Human, Recombinant (hFc) CD 137 4-1BB tumor necrosis factor receptor superfamily, member 9 CDw137 CD-137 CD137 ILA recombinant recombinant-proteins proteins protein

我们的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

Copyright © 2015-2024 TargetMol Chemicals Inc. All rights reserved. 沪ICP备20019793号-4

沪公网安备 31010602006700号

沪公网安备 31010602006700号

TargetMol Loading

陶术

生物

TargetMol^®中国区唯一合作伙伴

点击进入陶术生物官网

陶术生物

联系我们

电话：

400-820-0310

邮箱：

service@tsbiochem.com

QQ：

2881945090（终端用户）

2885109491（经销商）

经销：

终端：

地址：

上海市静安区江场三路238号8楼